Stock Fundamentals

Company Information

Company Name
Organon & Co
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
ISIN: US68622V1061
CIK: 0001821825
CUSIP: 68622V106
Currency: USD
Full Time Employees: 10,000
Phone: 551 430 6900
Fiscal Year End: December
IPO Date: Jun 02, 2021
Description:

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Address:

30 Hudson Street, Jersey City, NJ, United States, 07302

Directors & Officers

Name Title Year Born
Ms. Carrie Smith Cox Executive Chair of the Board 1959
Mr. Joseph T. Morrissey Jr. Chief Executive Officer 1965
Mr. Matthew M. Walsh C.F.A. Executive VP & CFO 1967
Ms. Rachel A. Stahler Executive VP, Chief Information Officer and Chief Digital & Growth Officer 1976
Mr. Kirke Weaver Executive VP, General Counsel & Corporate Secretary 1973
Dr. Juan Camilo Arjona Ferreira M.D. Executive VP, Head of Research & Development and Chief Medical Officer 1971
Ms. Jennifer Halchak Head of Investor Relations NA
Mr. Daniel Karp Chief Strategy Officer & Head of Corporate Development 1978
Mr. Aaron Falcione Executive VP & Chief Human Resources Officer 1971
Mr. Vittorio Nisita Executive VP and Head of Enterprise Services & Solutions 1968

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
May 06, 2025 Daniel Karp N/A Purchase 3.50K $8.24 $28.84K
May 06, 2025 Kirke Weaver N/A Purchase 8.05K $9.21 $74.09K
May 05, 2025 Kevin Ali N/A Purchase 34.00K $8.80 $299.20K
May 05, 2025 Kevin Ali N/A Purchase 34.00K $8.80 $299.20K
May 05, 2025 Matthew M Walsh N/A Purchase 11.40K $8.82 $100.55K
May 05, 2025 Matthew M Walsh N/A Purchase 11.40K $8.82 $100.55K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 36.92M Dec 31, 2025 14.06% $0.00 2.75%
BlackRock Inc 31.72M Mar 31, 2026 12.08% $0.00 2.43%
State Street Corp 9.96M Mar 31, 2026 3.79% $0.00 3.74%
LSV Asset Management 7.26M Mar 31, 2026 2.76% $0.09 -2.85%
Millennium Management LLC 6.78M Mar 31, 2026 2.58% $0.02 1,371.21%
Kahn Brothers & CO Inc /DE/ 5.54M Mar 31, 2026 2.11% $5.88 52.56%
Canada Pension Plan Investment Board 5.01M Mar 31, 2026 1.91% $0.02 106.24%
Geode Capital Management, LLC 4.76M Mar 31, 2026 1.81% $0.00 3.45%
Private Management Group Inc 4.37M Mar 31, 2026 1.67% $0.75 0.62%
Think Investments LP 4.00M Mar 31, 2026 1.52% $3.14 0.00%
UBS Group AG 3.47M Mar 31, 2026 1.32% $0.00 -19.17%
AQR Capital Management LLC 3.45M Mar 31, 2026 1.31% $0.01 -59.74%
Charles Schwab Investment Management Inc 3.36M Mar 31, 2026 1.28% $0.00 15.67%
Morgan Stanley - Brokerage Accounts 3.29M Mar 31, 2026 1.25% $0.00 3.57%
Dimensional Fund Advisors, Inc. 3.27M Mar 31, 2026 1.24% $0.00 -3.51%
First Trust Advisors L.P. 3.23M Mar 31, 2026 1.23% $0.01 78.10%
Two Sigma Investments LLC 3.14M Mar 31, 2026 1.19% $0.02 44.53%
D. E. Shaw & Co LP 2.64M Mar 31, 2026 1.01% $0.01 -21.91%
FMR Inc 2.56M Mar 31, 2026 0.97% $0.00 7,142.88%
HPM Partners LLC 2.31M Mar 31, 2026 0.88% $0.02 111.51%

Shares Statistics

Shares Outstanding: 262.60M
Shares Float: 261.08M
% Insiders: 39.40%
% Institutions: 7,762.00%
Short % Float: 8.67%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 15.85M 6.04% ▲ 0.02% Apr 30, 2026
2 Vanguard Total Stock Mkt Idx Inv 8.32M 3.17% ▲ 0.30% Apr 30, 2026
3 Vanguard Small Cap Index 6.00M 2.28% ▼ 0.06% Apr 30, 2026
4 Vanguard Small Cap Value Index Inv 3.85M 1.47% ▲ 0.75% Apr 30, 2026
5 Vanguard Equity-Income Inv 3.84M 1.46% ▼ 23.71% Mar 31, 2026
6 Vanguard Institutional Extnd Mkt Idx Tr 2.93M 1.12% ▲ 0.89% Apr 30, 2026
7 First Trust Health Care AlphaDEX® ETF 2.53M 0.96% ▲ 0.00% Apr 30, 2026
8 iShares S&P Small-Cap 600 Value ETF 2.42M 0.92% ▼ 0.17% Apr 30, 2026
9 State Street SPDR Port S&P 600 Sm CpETF 2.36M 0.90% ▲ 0.04% Apr 30, 2026
10 Vanguard Strategic Equity Inv 1.95M 0.74% ▼ 6.96% Mar 31, 2026

Valuation Metrics

Enterprise Value: $10.96B
Trailing P/E: 14.39
Forward P/E: 5.09

Financial Highlights

Market Cap: $3.51B
EBITDA: $1.60B
P/E Ratio: $14.39
Book Value: $3.44
Dividend/Share: $0.08
Dividend Yield: 0.60%
Earnings/Share: $0.93
Profit Margin: 3.99%
Operating Margin: 18.70%
ROA (TTM): 5.89%
ROE (TTM): 34.05%
Revenue (TTM): $6.16B
Revenue/Share (TTM): $23.69
Earnings Growth (YOY): 66.70%
Revenue Growth (YOY): -3.50%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 1.82x 11.55x 0.94x 2.55x 6.77x
2024-12-31 1.60x 18.91x 0.96x 2.86x 5.56x
2023-12-31 1.54x -125.80x 1.01x 2.52x 6.13x
2022-12-31 1.56x -10.05x 1.08x 4.04x 5.10x
2021-12-31 1.45x -6.09x 1.14x 7.42x 4.63x
2020-12-31 1.33x 0.00x 0.46x 474.50x 0.00x
2019-12-31 2.95x 0.02x 0.33x 641.17x 0.03x
2018-12-31 2.40x -0.03x 0.40x 60.13x -0.04x
2017-12-31 N/A N/A N/A 155.81x 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about OGN.US!